emedastine
Sign in to savethumb|upright=1|Eye drop of emedastine Emedastine (trade name Emadine) is a second generation antihistamine used in eye drops to alleviate the symptoms of allergic conjunctivitis. It acts as a H1 receptor antagonist. It works by blocking the action of histamine that causes allergic symptoms. It is used in form of the difumarate. The emedastine difumarate is a white, crystalline, water-soluble fine powder. Emedastine eye drops is usually applied twice a day to the affected eye. When the patients with allergic conjunctivitis were treated with 0.05% emedastine difumarate ophthalmic solution for
Key facts
- Drug.CAS_number
- 87233-61-2
- Drug.UNII
- 9J1H7Y9OJV
- Drug.ChemSpiderID
- 3106
- Drug.PubChem
- 3219
- Drug.ChEBI
- 4779
- Drug.ChEMBL
- 594
- Drug.DrugBank
- DB01084
- Drug.IUPHAR_ligand
- 7174
- Drug.KEGG
- D07890
- Drug.StdInChI
- 1S/C17H26N4O/c1-3-22-14-13-21-16-8-5-4-7-15(16)18-17(21)20-10-6-9-19(2)11-12-20/h4-5,7-8H,3,6,9-14H2,1-2H3
- Drug.StdInChIKey
- KBUZBQVCBVDWKX-UHFFFAOYSA-N
- Drug.SMILES
- CCOCCN1C2=CC=CC=C2N=C1N3CCCN(CC3)C
- Drug.IUPAC_name
- 1-(2-Ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1H-benzimidazole
- Drug.chemical_formula
- C17 H26 N4 O
- Drug.image
- Emedastine.png
- Drug.image_class
- skin-invert-image
via Wikipedia infobox
Research
105 papersvia PubMed
Article
5 sectionsContents
- Pharmacodynamics
- Pharmacokinetics
- Contraindications
- Adverse events
- References
thumb|upright=1|Eye drop of emedastine Emedastine (trade name Emadine) is a second generation antihistamine used in eye drops to alleviate the symptoms of allergic conjunctivitis. It acts as a H1 receptor antagonist. It works by blocking the action of histamine that causes allergic symptoms. It is used in form of the difumarate. The emedastine difumarate is a white, crystalline, water-soluble fine powder. Emedastine eye drops is usually applied twice a day to the affected eye. When the patients with allergic conjunctivitis were treated with 0.05% emedastine difumarate ophthalmic solution for six weeks, the signs and symptoms such as redness, itching and swelling of the eyes were relieved. Emedastine appears to be devoid of effects on adrenergic, dopaminergic and serotonin receptors. This drug was developed by Alcon, which is global medical company specializing in eye care products.
== Pharmacodynamics == Emedastine is significantly selective to H1 histamine receptors (Ki = 1.3 nM), whereas its affinities for other histamine receptors were low (H2: Ki = 49067 nM and H3: Ki = 12430 nM) ub in vitro study. Topical ocular administration of emedastine inhibits histamine-stimulated vascular permeability in the conjunctiva as a concentration-dependent manner in in vitro study.